These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 23011726)

  • 1. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
    Long-Smith CM; Manning S; McClean PL; Coakley MF; O'Halloran DJ; Holscher C; O'Neill C
    Neuromolecular Med; 2013 Mar; 15(1):102-14. PubMed ID: 23011726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
    McClean PL; Parthsarathy V; Faivre E; Hölscher C
    J Neurosci; 2011 Apr; 31(17):6587-94. PubMed ID: 21525299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer's disease.
    Ochiai T; Sano T; Nagayama T; Kubota N; Kadowaki T; Wakabayashi T; Iwatsubo T
    Neurobiol Dis; 2021 Nov; 159():105510. PubMed ID: 34537327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin ameliorates insulin signalling pathway in brain of Alzheimer's disease transgenic mice.
    Feng HL; Dang HZ; Fan H; Chen XP; Rao YX; Ren Y; Yang JD; Shi J; Wang PW; Tian JZ
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):734-741. PubMed ID: 27466310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.
    Moloney AM; Griffin RJ; Timmons S; O'Connor R; Ravid R; O'Neill C
    Neurobiol Aging; 2010 Feb; 31(2):224-43. PubMed ID: 18479783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.
    Zhang W; Zhang W; Li Z; Hao J; Zhang Z; Liu L; Mao N; Miao J; Zhang L
    Pharmacol Biochem Behav; 2012 Jan; 100(3):361-9. PubMed ID: 21993310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Ruan L; Kang Z; Pei G; Le Y
    Curr Alzheimer Res; 2009 Dec; 6(6):531-40. PubMed ID: 19747158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.
    Ma QL; Yang F; Rosario ER; Ubeda OJ; Beech W; Gant DJ; Chen PP; Hudspeth B; Chen C; Zhao Y; Vinters HV; Frautschy SA; Cole GM
    J Neurosci; 2009 Jul; 29(28):9078-89. PubMed ID: 19605645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
    Bomfim TR; Forny-Germano L; Sathler LB; Brito-Moreira J; Houzel JC; Decker H; Silverman MA; Kazi H; Melo HM; McClean PL; Holscher C; Arnold SE; Talbot K; Klein WL; Munoz DP; Ferreira ST; De Felice FG
    J Clin Invest; 2012 Apr; 122(4):1339-53. PubMed ID: 22476196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
    Duffy AM; Hölscher C
    Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EK100 and Antrodin C Improve Brain Amyloid Pathology in APP/PS1 Transgenic Mice by Promoting Microglial and Perivascular Clearance Pathways.
    Tsay HJ; Liu HK; Kuo YH; Chiu CS; Liang CC; Chung CW; Chen CC; Chen YP; Shiao YJ
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques.
    Natunen T; Martiskainen H; Marttinen M; Gabbouj S; Koivisto H; Kemppainen S; Kaipainen S; Takalo M; Svobodová H; Leppänen L; Kemiläinen B; Ryhänen S; Kuulasmaa T; Rahunen E; Juutinen S; Mäkinen P; Miettinen P; Rauramaa T; Pihlajamäki J; Haapasalo A; Leinonen V; Tanila H; Hiltunen M
    Mol Neurodegener; 2020 Nov; 15(1):66. PubMed ID: 33168021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease.
    Kamphuis W; Kooijman L; Orre M; Stassen O; Pekny M; Hol EM
    Glia; 2015 Jun; 63(6):1036-56. PubMed ID: 25731615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity.
    Jantrapirom S; Nimlamool W; Chattipakorn N; Chattipakorn S; Temviriyanukul P; Inthachat W; Govitrapong P; Potikanond S
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.